Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation (Q37736501)

22 August 2017

1 reference

title

Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation (English)

1 reference

22 August 2017

0 references

organ transplantation

1 reference

1 reference

1 reference

Maya Campara

1

1 reference

22 August 2017

Ivo G Tzvetanov

series ordinal

2

1 reference

22 August 2017

Jose Oberholzer

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

Expert Opinion on Biological Therapy

22 August 2017

1 reference

22 August 2017

10

1 reference

22 August 2017

959-969

1 reference

22 August 2017

6

1 reference

T cell growth factor receptors. Quantitation, specificity, and biological relevance

22 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

A humanized antibody that binds to the interleukin 2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Two-dose daclizumab induction in pediatric renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Early experience with two-dose daclizumab in the prevention of acute rejection in cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Induction therapy with daclizumab in heart transplantation--how many doses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

The efficacy of daclizumab for intestinal transplantation: preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Daclizumab to prevent rejection after cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Daclizumab versus anti-thymocyte globulin-fresenius as induction therapy for low-risk kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

A prospective, pilot study of early corticosteroid cessation in high-immunologic-risk patients: the Cincinnati experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Zenapax versus OKT-3 prophylaxis in immunologically high-risk kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Comparative study of muromonab-CD3 (OKT3) versus daclizumab (Zenapax) in cardiac transplantation at our center

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Daclizumab induction in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485187

10.1517/14712598.2010.485187

21 January 2018

Identifiers

DOI

1 reference

release_vhuween4uvfo5hpwoojc4p2hqq

22 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vhuween4uvfo5hpwoojc4p2hqq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference